The RNA Interference Effector Protein Argonaute 2 Functions as a Restriction Factor Against SARS-CoV-2

被引:5
|
作者
Lopez-Orozco, Joaquin [1 ]
Fayad, Nawell [1 ]
Khan, Juveriya Qamar [3 ]
Felix-Lopez, Alberto [2 ]
Elaish, Mohamed [1 ]
Rohamare, Megha [3 ]
Sharma, Maansi [3 ]
Falzarano, Darryl [4 ,5 ]
Pelletier, Jerry [6 ]
Wilson, Joyce [3 ]
Hobman, Tom C. [1 ,2 ,7 ]
Kumar, Anil [3 ]
机构
[1] Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB, Canada
[2] Univ Alberta, Fac Med & Dent, Dept Med Microbiol & Immunol, Edmonton, AB, Canada
[3] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK, Canada
[4] Univ Saskatchewan, Vaccine & Infect Dis Org VIDO, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK, Canada
[6] McGill Univ, Dept Biochem, Montreal, PQ, Canada
[7] Univ Alberta, Li Ka Shing Inst Virol, Edmonton, AB, Canada
基金
加拿大健康研究院; 加拿大自然科学与工程研究理事会;
关键词
innate immunity; coronaviruses; viral microRNAs; RNAi; Ago2; ANTIVIRAL IMMUNITY; STRESS GRANULES; DICER; VIRUSES; PHOSPHORYLATION; INHIBITION; EVOLUTION; RESPONSES; DEFENSE;
D O I
10.1016/j.jmb.2023.168170
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Argonaute 2 (Ago2) is a key component of the RNA interference (RNAi) pathway, a gene-regulatory sys-tem that is present in most eukaryotes. Ago2 uses microRNAs (miRNAs) and small interfering RNAs (siR-NAs) for targeting to homologous mRNAs which are then degraded or translationally suppressed. In plants and invertebrates, the RNAi pathway has well-described roles in antiviral defense, but its function in limiting viral infections in mammalian cells is less well understood. Here, we examined the role of Ago2 in replication of the betacoronavirus SARS-CoV-2, the etiologic agent of COVID-19. Microscopic analyses of infected cells revealed that a pool of Ago2 closely associates with viral replication sites and gene ab-lation studies showed that loss of Ago2 resulted in over 1,000-fold increase in peak viral titers. Replication of the alphacoronavirus 229E was also significantly increased in cells lacking Ago2. The antiviral activity of Ago2 was dependent on both its ability to bind small RNAs and its endonuclease function. Interestingly, in cells lacking Dicer, an upstream component of the RNAi pathway, viral replication was the same as in par-ental cells. This suggests that the antiviral activity of Ago2 is independent of Dicer processed miRNAs. Deep sequencing of infected cells by other groups identified several SARS-CoV-2-derived small RNAs that bind to Ago2. A mutant virus lacking the most abundant ORF7A-derived viral miRNA was found to be significantly less sensitive to Ago2-mediated restriction. This combined with our findings that endonu-clease and small RNA-binding functions of Ago2 are required for its antiviral function, suggests that Ago2-small viral RNA complexes target nascent viral RNA produced at replication sites for cleavage. Further studies are required to elucidate the processing mechanism of the viral small RNAs that are used by Ago2 to limit coronavirus replication.Crown Copyright & COPY; 2023 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Antiviral drugs against SARS-CoV-2
    Aiello, Tommaso Francesco
    Garcia-Vidal, Carolina
    Soriano, Alex
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 10 - 15
  • [42] Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
    Tong, X.
    McNamara, R. P.
    Avendano, M. J.
    Serrano, E. F.
    Garcia-Salum, T.
    Pardo-Roa, C.
    Bertera, H. L.
    Chicz, T. M.
    Levican, J.
    Poblete, E.
    Salinas, E.
    Munoz, A.
    Riquelme, A.
    Alter, G.
    Medina, R. A.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [43] Phytochemicals Against SARS-COV-2 Infection
    Agrawal, Pawan K. K.
    Blunden, Gerald
    NATURAL PRODUCT COMMUNICATIONS, 2023, 18 (02)
  • [44] Disinfectants against SARS-CoV-2: A Review
    Xiao, Shuqi
    Yuan, Zhiming
    Huang, Yi
    VIRUSES-BASEL, 2022, 14 (08):
  • [45] Development of vaccines against SARS-CoV-2
    Leon-Lara, Ximena
    Otero-Mendoza, Francisco
    ACTA PEDIATRICA DE MEXICO, 2020, 41 (04): : S23 - S26
  • [46] Therapeutic nanobodies against SARS-CoV-2
    Güttler T.
    Dobbelstein M.
    Görlich D.
    BIOspektrum, 2022, 28 (1) : 39 - 42
  • [47] Vaccinating children against SARS-CoV-2
    Lavine, Jennie S.
    Bjornstad, Ottar
    Antia, Rustom
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [48] Antivirals against SARS-CoV-2 by autumn?
    Smith, David
    Gill, Dipender
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
  • [49] Vaccinations against SARS-CoV-2 and the Skin
    Mockenhaupt, Maja
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (03): : 223 - 224
  • [50] Timing vaccination against SARS-CoV-2
    Coline Barnoud
    Chen Wang
    Christoph Scheiermann
    Cell Research, 2021, 31 : 1146 - 1147